Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach

View More View Less
  • a From Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts; Division of Medical Oncology, Moffitt Cancer Center, Tampa, Florida; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Division of Medical Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania; Division of Oncology, Stanford University Medical Center, Palo Alto, California; Division of Hematology/Oncology, The University of California, San Francisco, California; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Restricted access

Testicular cancer is the most common cancer in men aged 15 to 40 years in the United States, Canada, and many European countries. Given the excellent prognosis of most men with testicular cancer, updates in care after treatment have become very important. This article provides a review of the available evidence, integrated with expert medical judgment, in the area of testicular cancer follow-up.

Correspondence: Clair J. Beard, MD, Dana-Farber Cancer Institute/Brigham and Women's Hospital, 75 Francis Street, ASB-1, Level 2, Boston, MA 02115. E-mail: cbeard@lroc.harvard.edu
  • 1.

    Nigam M, Aschebrook-Kilfoy B, Shikanov S, Eggener S. Increasing incidence of testicular cancer in the United States and Europe World J Urol 2015;33:623631.

    • Search Google Scholar
    • Export Citation
  • 2.

    Rosen A, Jayram G, Drazer M, Eggener SE. Global trends in testicular cancer incidence and mortality. Eur Urol 2011;60:374379.

  • 3.

    Power DA, Brown RS, Brock CS. Trends in testicular carcinoma in England and Wales, 1971-99. BJU Int 2001;87:361365.

  • 4.

    Daugaard G, Gundgaard MG, Mortensen MS. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 2014;32:38173823.

    • Search Google Scholar
    • Export Citation
  • 5.

    Kollmannsberger C, Tandstand T, Bedard PL. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015;33:5157.

    • Search Google Scholar
    • Export Citation
  • 6.

    Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007;64:182197.

    • Search Google Scholar
    • Export Citation
  • 7.

    Vesprini D, Chung P, Tolan S. Utility of serum tumor markers during surveillance for stage I seminoma. Cancer 2012;118:52455250.

  • 8.

    Motzer RJ, Jonasch E, Agarwal N. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 2, 2015. Available at: NCCN.org. Accessed May 27, 2015.

    • Search Google Scholar
    • Export Citation
  • 9.

    Yu HY, Madison RA, Setodji CM, Saigal CS. Quality of surveillance for stage I testis cancer in the community. J Clin Oncol 2009;27:43274332.

  • 10.

    Ernst DS, Brasher P, Venner PM. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol 2005;12(2):2575-80.

    • Search Google Scholar
    • Export Citation
  • 11.

    Freedman LS, Jones WG, Peckham MJ. Histopathology in the prediction of relapse of patients with stage i testicular teratoma treated by orchidectomy alone. Lancet 1987;330:294298.

    • Search Google Scholar
    • Export Citation
  • 12.

    Ondrus D, Matoska J, Belan V. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 1998;33:562566.

    • Search Google Scholar
    • Export Citation
  • 13.

    Freedman LS, Parkinson MC, Jones WG. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987;2:294298.

    • Search Google Scholar
    • Export Citation
  • 14.

    Albers P, Siener R, Kliesch S. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003;21:15051512.

    • Search Google Scholar
    • Export Citation
  • 15.

    Tandstad T, Dahl O, Cohn-Cedermark G. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009;27 21222128.

    • Search Google Scholar
    • Export Citation
  • 16.

    Sturgeon JF, Moore MJ, Kakiashvili DM. Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience. Eur Urol 2011;59:556562.

    • Search Google Scholar
    • Export Citation
  • 17.

    Kollmannsberger C, Tyldesley S, Moore C. Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies. Ann Oncol 2011;22:808814.

    • Search Google Scholar
    • Export Citation
  • 18.

    Rustin GJ, Mead GM, Stenning SP. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197—the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25:13101315.

    • Search Google Scholar
    • Export Citation
  • 19.

    Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003;111:7683; discussion 83–75.

  • 20.

    Read G, Stenning SP, Cullen MH. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992;10:17621768.

    • Search Google Scholar
    • Export Citation
  • 21.

    Colls BM, Harvey VJ, Skelton L. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999;83:7682.

    • Search Google Scholar
    • Export Citation
  • 22.

    Cathomas R, Hartmann M, Krege S. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie 2011;34:5964.

    • Search Google Scholar
    • Export Citation
  • 23.

    Souchon R, Hartmann M, Krege S. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol 2011;187:158166.

    • Search Google Scholar
    • Export Citation
  • 24.

    Schmoll HJ, Jordan K, Huddart R. Testicular non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v147154.

    • Search Google Scholar
    • Export Citation
  • 25.

    van As NJ, Gilbert DC, Money-Kyrle J. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse. Br J Cancer 2008;98:18941902.

    • Search Google Scholar
    • Export Citation
  • 26.

    Vergouwe Y, Steyerberg EW, Eijkemans MJ. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003;21:40924099.

    • Search Google Scholar
    • Export Citation
  • 27.

    Bokemeyer C, Kuczyk MA, Serth J. Treatment of clinical stage I testicular cancer and a possible role for new biological prognostic parameters. J Cancer Res Clin Oncol 1996;122:575584.

    • Search Google Scholar
    • Export Citation
  • 28.

    Divrik RT, Akdogan B, Ozen H, Zorlu F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified? J Urol 2006;176:14241429; discussion 1429–1430.

    • Search Google Scholar
    • Export Citation
  • 29.

    Sogani PC, Perrotti M, Herr HW. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855858.

  • 30.

    Maroto P, Garcia del Muro X, Aparicio J. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005;16:19151920.

    • Search Google Scholar
    • Export Citation
  • 31.

    Albers P, Siener R, Krege S. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008;26:29662972.

    • Search Google Scholar
    • Export Citation
  • 32.

    Kollmannsberger C, Moore C, Chi KN. Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy. Ann Oncol 2010;21:12961301.

    • Search Google Scholar
    • Export Citation
  • 33.

    Steiner H, Zangerl F, Stohr B. Results of bilateral nerve sparing laparoscopic retroperitoneal lymph node dissection for testicular cancer. J Urol 2008;180:13481352; discussion 1352–1343.

    • Search Google Scholar
    • Export Citation
  • 34.

    Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 1990;144:11601163.

  • 35.

    Weissbach L, Bussar-Maatz R, Flechtner H. RPLND or primary chemotherapy in clinical stage IIA/B nonseminomatous germ cell tumors? Results of a prospective multicenter trial including quality of life assessment. Eur Urol 2000;37:582594.

    • Search Google Scholar
    • Export Citation
  • 36.

    Stephenson AJ, Bosl GJ, Motzer RJ. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer. J Clin Oncol 2007;25:55975602.

    • Search Google Scholar
    • Export Citation
  • 37.

    Donohue JP, Thornhill JA, Foster RS. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995;153:8589.

    • Search Google Scholar
    • Export Citation
  • 38.

    Rabbani F, Sheinfeld J, Farivar-Mohseni H. Low-volume nodal metastases detected at retroperitoneal lymphadenectomy for testicular cancer: pattern and prognostic factors for relapse. J Clin Oncol 2001;19:20202025.

    • Search Google Scholar
    • Export Citation
  • 39.

    Williams SD, Stablein DM, Einhorn LH. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:14331438.

    • Search Google Scholar
    • Export Citation
  • 40.

    Horwich A, Stenning S. Initial chemotherapy for stage II testicular non-seminoma. World J Urol 1994;12:148150.

  • 41.

    Peckham MJ, Hendry WF. Clinical stage II non-seminomatous germ cell testicular tumours. Results of management by primary chemotherapy. Br J Urol 1985;57:763768.

    • Search Google Scholar
    • Export Citation
  • 42.

    Vogelzang NJ, Fraley EE, Lange PH. Stage II nonseminomatous testicular cancer: a 10-year experience. J Clin Oncol 1983;1:171178.

  • 43.

    Motzer RJ, Sheinfeld J, Mazumdar M. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors. J Clin Oncol 1995;13:27002704.

    • Search Google Scholar
    • Export Citation
  • 44.

    Grimison PS, Stockler MR, Thomson DB. Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial. J Natl Cancer Inst 2010;102:12531262.

    • Search Google Scholar
    • Export Citation
  • 45.

    Logothetis CJ, Swanson DA, Dexeus F. Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients. J Clin Oncol 1987;5:906911.

    • Search Google Scholar
    • Export Citation
  • 46.

    Krege S, Beyer J, Souchon R. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008;53:497513.

    • Search Google Scholar
    • Export Citation
  • 47.

    Ehrlich Y, Brames MJ, Beck SD. Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010;28:531536.

    • Search Google Scholar
    • Export Citation
  • 48.

    Beck SD, Foster RS. Management of the post chemotherapy subcentimeter residual mass: the case for observation. World J Urol 2009;27:485488.

    • Search Google Scholar
    • Export Citation
  • 49.

    Panicek DM, Toner GC, Heelan RT, Bosl GJ. Nonseminomatous germ cell tumors: enlarging masses despite chemotherapy. Radiology 1990;175:499502.

  • 50.

    Fossa SD, Aass N, Ous S. Histology of tumor residuals following chemotherapy in patients with advanced nonseminomatous testicular cancer. J Urol 1989;142:12391242.

    • Search Google Scholar
    • Export Citation
  • 51.

    Xiao H, Sheinfeld J, Motzer RJ. Adjuvant chemotherapy for testicular cancer. Surg Oncol Clin N Am 1997;6:863878.

  • 52.

    Kuczyk M, Machtens S, Stief C, Jonas U. Management of the post-chemotherapy residual mass in patients with advanced stage non-seminomatous germ cell tumors (NSGCT). Int J Cancer 1999;83:852855.

    • Search Google Scholar
    • Export Citation
  • 53.

    Toner GC, Panicek DM, Heelan RT. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990;8:16831694.

    • Search Google Scholar
    • Export Citation
  • 54.

    Baniel J, Foster RS, Gonin R. Late relapse of testicular cancer. J Clin Oncol 1995;13:11701176.

  • 55.

    Albers P, Ganz A, Hannig E. Salvage surgery of chemorefractory germ cell tumors with elevated tumor markers. J Urol 2000;164:381384.

  • 56.

    Geldart TR, Gale J, McKendrick J. Late relapse of metastatic testicular nonseminomatous germ cell cancer: surgery is needed for cure. BJU Int 2006;98:353358.

    • Search Google Scholar
    • Export Citation
  • 57.

    Gietema JA, Meinardi MT, Sleijfer DT. Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002;13:16161620.

    • Search Google Scholar
    • Export Citation
  • 58.

    Fossa SD, Stenning SP, Gerl A. Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer 1999;80:13921399.

    • Search Google Scholar
    • Export Citation
  • 59.

    Lorch A, Beyer J, Bascoul-Mollevi C. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy. J Clin Oncol 2010;28:49064911.

    • Search Google Scholar
    • Export Citation
  • 60.

    Einhorn LH, Williams SD, Chamness A. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 2007;357:340348.

    • Search Google Scholar
    • Export Citation
  • 61.

    Motzer RJ, Geller NL, Tan CC. Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979–1989). Cancer 1991;67:13051310.

    • Search Google Scholar
    • Export Citation
  • 62.

    Warde P, Specht L, Horwich A. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002;20:44484452.

    • Search Google Scholar
    • Export Citation
  • 63.

    Chung PW, Daugaard G, Tyldesley S. Prognostic factors for relapse in stage I seminoma managed with surveillance: a validation study [abstract]. J Clin Oncol 2010;28(Suppl):Abstract 4535.

    • Search Google Scholar
    • Export Citation
  • 64.

    Aparicio J, Maroto P, del Muro XG. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol 2011;29:46774681.

    • Search Google Scholar
    • Export Citation
  • 65.

    Motzer RJ, Agarwal N, Beard C. NCCN Clinical Practice Guidelines in Oncology: Testicular Cancer. Version 1, 2011. To view the most recent version of these guidelines, visit NCCN.org.

    • Search Google Scholar
    • Export Citation
  • 66.

    Beard CJ, Travis LB, Chen MH. Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer 2013;119:27712777.

  • 67.

    Oliver RT, Mead GM, Rustin GJ. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011;29:957962.

    • Search Google Scholar
    • Export Citation
  • 68.

    Fossa SD, Horwich A, Russell JM. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 1999;17:1146.

    • Search Google Scholar
    • Export Citation
  • 69.

    Mead GM, Fossa SD, Oliver RT. Randomized trials in 2466 patients with stage I seminoma: patterns of relapse and follow-up. J Natl Cancer Inst 2011;103:241249.

    • Search Google Scholar
    • Export Citation
  • 70.

    Horwich A, Sleijfer DT, Fossa SD. Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol 1997;15: 18441852.

    • Search Google Scholar
    • Export Citation
  • 71.

    Schmidberger H, Bamberg M, Meisner C. Radiotherapy in stage IIA and IIB testicular seminoma with reduced portals: a prospective multicenter study. Int J Radiat Oncol Biol Phys 1997;39:321326.

    • Search Google Scholar
    • Export Citation
  • 72.

    Classen J, Schmidberger H, Meisner C. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol 2003;21:11011106.

    • Search Google Scholar
    • Export Citation
  • 73.

    Wilder RB, Buyyounouski MK, Efstathiou JA. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biop Phys 2012;83:445452.

    • Search Google Scholar
    • Export Citation
  • 74.

    Classen J, Souchon R, Hehr T, Bamberg M. Radiotherapy for early stages testicular seminoma: patterns of care study in Germany. Radiother Oncol 2002;63:179186.

    • Search Google Scholar
    • Export Citation
  • 75.

    Garcia-del-Muro X, Maroto P, Guma J. Chemotherapy as an alternative to radiotherapy in the treatment of stage IIA and IIB testicular seminoma: a Spanish Germ Cell Cancer Group Study. J Clin Oncol 2008;26:54165421.

    • Search Google Scholar
    • Export Citation
  • 76.

    Warde P, Huddart R, Bolton D. Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. Urology 2011;78:S435443.

    • Search Google Scholar
    • Export Citation
  • 77.

    Herr HW, Sheinfeld J, Puc HS. Surgery for a post-chemotherapy residual mass in seminoma. J Urol 1997;157:860862.

  • 78.

    Flechon A, Bompas E, Biron P, Droz JP. Management of post-chemotherapy residual masses in advanced seminoma. J Urol 2002;168:19751979.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 134 77 7
PDF Downloads 53 32 2
EPUB Downloads 0 0 0